Gene-modified dendritic cells for immunotherapy against cancer.
Dendritic cells (DCs) are described as professional antigen-presenting cells because of their superior T-cell stimulatory capacity. For this reason, attention is being focused on using DCs for clinical applications to treat cancer patients. Although preclinical studies are promising, the majority of clinical studies with DCs have not fulfilled the expectations, yet. The field of DC biology has progressed rapidly over the past years, leading to several options for the improvement of vaccination. Among the different parameters to investigate, this review focuses on the efficiency and biological and functional consequences of different gene transfer methods into different subsets of human DCs. Another important consideration for DC-based vaccination is the elucidation of the role of maturation and apoptosis during DC differentiation.
Lundqvist
Andreas
A
Cancer Center Karolinska, Immune and Gene Therapy, Department of Oncology and Pathology, Radiumhemmet, Karolinska Institutet, Stockholm, Sweden.
Pisa
Pavel
P
D000256:Adenoviridae / Q000235:genetics; D017951:Antigen Presentation; D017209:Apoptosis; D002450:Cell Communication; D002454:Cell Differentiation; D019070:Cell Lineage; D003713:Dendritic Cells / Q000276:immunology* / Q000502:physiology; D018014:Gene Transfer Techniques; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology